نمایش مختصر رکورد

dc.date.accessioned1399-07-08T17:52:55Zfa_IR
dc.date.accessioned2020-09-29T17:52:56Z
dc.date.available1399-07-08T17:52:55Zfa_IR
dc.date.available2020-09-29T17:52:56Z
dc.date.issued2011-02-01en_US
dc.date.issued1389-11-12fa_IR
dc.identifier.citation(2011). Survival of Patients with Transitional Cell Carcinoma of the Urinary Bladder in Indonesia: A Single Institution Review. Asian Pacific Journal of Cancer Prevention, 12(2), 549-553.en_US
dc.identifier.issn1513-7368
dc.identifier.issn2476-762X
dc.identifier.urihttp://journal.waocp.org/article_25554.html
dc.identifier.urihttps://iranjournals.nlai.ir/handle/123456789/31283
dc.description.abstract<br/><b>Objective</b>: To describe for the first time the survival of bladder transitional cell carcinoma (TCC) in Indonesia,according to clinicopathological characteristics. Materials and <br/><b>Methods</b>: Retrospective study of bladder TCCsurvival in a single institution, Cipto Mangunkusumo Hospital, Indonesia’s national tertiary referral centre,between the years 1995 and 2005. The Kaplan-Meier method was used to determine the overall survival (OS).<br/><b>Results</b>: The evaluable data covered 254 cases of primary bladder TCC, in which 95 (37.4%) were non muscleinvasivebladder cancer (NMIBC), and 159 cases (62.6%) were muscle-invasive (MIBC). Of these, 105 cases(41.4%) with a follow-up period up to five years were eligible for survival analysis. The mean age was 56.5 +/-12.1 years old, with a male to female ratio of 6:1. The 5-year OS for all bladder TCC was 27.6%, with a meansurvival time of 32.6 months. For NMIBC, the 5-year OS was 53.8% with a mean survival of 54.5 months. ForMIBC, the 5-year OS was 19% with a mean survival of 25.4 months. Regarding pathological stage, the 5-yearOS for stage 0, I, II, III, and IV was 83.3%, 45%, 30%, 18.8%, and 9.1%, respectively. <br/><b>Conclusion</b>: The overallsurvival of bladder TCC in Indonesia is low compared to other countries. Possible explanations include thehigh number of advanced-stage tumours at initial presentation, under-staging, significant number of treatmentrefusal by our patients, and the non-standardized use of adjuvant therapy in our centre.en_US
dc.format.extent321
dc.format.mimetypeapplication/pdf
dc.languageEnglish
dc.language.isoen_US
dc.publisherWest Asia Organization for Cancer Prevention (WAOCP)en_US
dc.relation.ispartofAsian Pacific Journal of Cancer Preventionen_US
dc.subjectLong term survivalen_US
dc.subjecttreatment modalitiesen_US
dc.subjectmuscle invasive bladder canceren_US
dc.subjectIndonesiaen_US
dc.titleSurvival of Patients with Transitional Cell Carcinoma of the Urinary Bladder in Indonesia: A Single Institution Reviewen_US
dc.typeTexten_US
dc.citation.volume12
dc.citation.issue2
dc.citation.spage549
dc.citation.epage553


فایل‌های این مورد

Thumbnail

این مورد در مجموعه‌های زیر وجود دارد:

نمایش مختصر رکورد